...
search icon
stok-img

Stoke Therapeutics Inc Share Price

STOK
NSQ
$34.37
+$3.39
(10.94%)
1D
Industry: Biotechnology Sector: Health Care

Stoke Therapeutics Inc Analyst Forecast

Stoke Therapeutics Inc Share Price Chart

Stoke Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.77B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.19M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.11
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.35 L
$38.69 H
$34.37

About Stoke Therapeutics Inc, Common Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. more

Industry: BiotechnologySector: Health Care

Stoke Therapeutics Inc Stock Returns

Time FrameSTOKSectorS&P500
1-Week Return7.78%1.07%0.74%
1-Month Return19.67%1.46%1.28%
3-Month Return20.68%3.51%3.6%
6-Month Return85.88%15.29%7.31%
1-Year Return269.57%7.7%11.97%
3-Year Return294.15%21.02%72.07%
5-Year Return-43.53%37.81%76.01%
10-Year Return34.42%139.15%258.47%

Stoke Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-3.00M12.40M8.78M36.55M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":8.21,"profit":true},{"date":"2022-12-31","value":33.94,"profit":true},{"date":"2023-12-31","value":24.02,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.93M2.23M3.54M4.73M4.44M[{"date":"2020-12-31","value":40.73,"profit":true},{"date":"2021-12-31","value":47.16,"profit":true},{"date":"2022-12-31","value":74.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.93,"profit":true}]
Gross Profit(1.93M)(2.23M)12.40M8.78M36.55M[{"date":"2020-12-31","value":-5.27,"profit":false},{"date":"2021-12-31","value":-6.1,"profit":false},{"date":"2022-12-31","value":33.94,"profit":true},{"date":"2023-12-31","value":24.02,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin-(74.33%)100.00%100.00%100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-74.33,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses53.04M86.06M116.76M123.55M137.93M[{"date":"2020-12-31","value":38.46,"profit":true},{"date":"2021-12-31","value":62.4,"profit":true},{"date":"2022-12-31","value":84.65,"profit":true},{"date":"2023-12-31","value":89.58,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(53.04M)(86.06M)(104.36M)(114.77M)(101.37M)[{"date":"2020-12-31","value":-5304400000,"profit":false},{"date":"2021-12-31","value":-8606500000,"profit":false},{"date":"2022-12-31","value":-10435600000,"profit":false},{"date":"2023-12-31","value":-11477300000,"profit":false},{"date":"2024-12-31","value":-10137200000,"profit":false}]
Total Non-Operating Income/Expense1.54M380.00K6.41M18.87M25.03M[{"date":"2020-12-31","value":6.17,"profit":true},{"date":"2021-12-31","value":1.52,"profit":true},{"date":"2022-12-31","value":25.61,"profit":true},{"date":"2023-12-31","value":75.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(52.24M)(85.81M)(101.07M)(104.70M)(88.98M)[{"date":"2020-12-31","value":-5224300000,"profit":false},{"date":"2021-12-31","value":-8580500000,"profit":false},{"date":"2022-12-31","value":-10106700000,"profit":false},{"date":"2023-12-31","value":-10469900000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
Income Taxes(1.63M)(1.09M)(7.96M)4.56M(88.98M)[{"date":"2020-12-31","value":-35.78,"profit":false},{"date":"2021-12-31","value":-23.99,"profit":false},{"date":"2022-12-31","value":-174.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-1950.86,"profit":false}]
Income After Taxes(50.61M)(84.71M)(93.11M)(109.26M)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(52.24M)(85.81M)(101.07M)(103.40M)(88.98M)[{"date":"2020-12-31","value":-5224300000,"profit":false},{"date":"2021-12-31","value":-8580500000,"profit":false},{"date":"2022-12-31","value":-10106700000,"profit":false},{"date":"2023-12-31","value":-10339600000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(50.61M)(84.71M)(93.11M)(104.70M)(88.98M)[{"date":"2020-12-31","value":-5061100000,"profit":false},{"date":"2021-12-31","value":-8471100000,"profit":false},{"date":"2022-12-31","value":-9311000000,"profit":false},{"date":"2023-12-31","value":-10469900000,"profit":false},{"date":"2024-12-31","value":-8898100000,"profit":false}]
EPS (Diluted)(1.56)(2.33)(2.60)(2.37)(1.68)[{"date":"2020-12-31","value":-156,"profit":false},{"date":"2021-12-31","value":-233,"profit":false},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-237,"profit":false},{"date":"2024-12-31","value":-167.91,"profit":false}]

Stoke Therapeutics Inc Ratios

Stoke Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

STOK
Cash Ratio 5.95
Current Ratio 6.53

Stoke Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

STOK
ROA (LTM) 5.20%
ROE (LTM) 15.02%

Stoke Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

STOK
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Stoke Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

STOK
Trailing PE 45.56
Forward PE 204.08
P/S (TTM) 8.61
P/B 5.92
Price/FCF NM
EV/R 7.68
EV/Ebitda 54.30

FAQs

What is Stoke Therapeutics Inc share price today?

Stoke Therapeutics Inc (STOK) share price today is $34.37

Can Indians buy Stoke Therapeutics Inc shares?

Yes, Indians can buy shares of Stoke Therapeutics Inc (STOK) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in STOK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Stoke Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Stoke Therapeutics Inc (STOK) via the Vested app. You can start investing in Stoke Therapeutics Inc (STOK) with a minimum investment of $1.

How to invest in Stoke Therapeutics Inc shares from India?

You can invest in shares of Stoke Therapeutics Inc (STOK) via Vested in three simple steps:

  • Click on Sign Up or Invest in STOK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Stoke Therapeutics Inc shares
What is Stoke Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Stoke Therapeutics Inc (STOK) is $38.69. The 52-week low price of Stoke Therapeutics Inc (STOK) is $5.35.

What is Stoke Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Stoke Therapeutics Inc (STOK) is

What is Stoke Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Stoke Therapeutics Inc (STOK) is 5.92

What is Stoke Therapeutics Inc dividend yield?

The dividend yield of Stoke Therapeutics Inc (STOK) is 0.00%

What is the Market Cap of Stoke Therapeutics Inc?

The market capitalization of Stoke Therapeutics Inc (STOK) is $1.77B

What is Stoke Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Stoke Therapeutics Inc is STOK

How Can Investors Use Stoke Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Stoke Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Stoke Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Stoke Therapeutics Inc shares for Indian investors?

When investing in Stoke Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Stoke Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Stoke Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Stoke Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Stoke Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top